Table 4 Time to progression (TTP) according to biomarkers expression considered as per clinical practicea
No. | HR (95% CI)b | Median TTP, months (95% CI) | p | |
|---|---|---|---|---|
AR status | ||||
< 1% | 17 | 1.00 | 12.0 (4.3-48.1) | |
≥ 1% | 85 | 0.96 (0.56-1.66) | 16.1 (13.0-19.0) | 0.884 |
< 10% | 26 | 1.00 | 13.8 (11.0-42.1) | |
≥ 10% | 76 | 0.98 (0.61-1.57) | 16.0 (13.0-19.0) | 0.935 |
AR/ER ratio | ||||
< 0.90 (best cutoff) | 52 | 1.00 | 12.9 (11.0-17.1) | |
≥ 0.90 (best cutoff) | 50 | 0.83 (0.55-1.24) | 18.0 (14.0-24.6) | 0.362 |
AR/PgR ratio | ||||
< 0.96 (best cutoff) | 34 | 1.00 | 16.8 (12.1-47.9) | |
≥ 0.96 (best cutoff) | 68 | 1.65 (1.05-2.61) | 16.0 (12.4-19.0) | 0.028 |
PgR status | ||||
< 1% | 22 | 1.00 | 10.5 (4.0-17.0) | |
≥ 1% | 80 | 2.18 (1.34-3.55) | 17.0 (14.0-24.7) | 0.001 |
Ki67 status | ||||
< 20% | 63 | 1.00 | 17.6 (14.8-22.1) | |
≥ 20% | 38 | 1.60 (1.05-2.45) | 12.0 (8.2-16.1) | 0.028 |
HER2 status | ||||
negative | 88 | 1.00 | 15.8 (12.9-19.0) | |
positive | 14 | 1.15 (0.65-2.02) | 18.0 (7.0-46.0) | 0.929 |